Overview
Inotiv Q4 FY 2025 revenue rose 5.9% to $138.1 mln, beating analyst expectations
Adjusted EBITDA for Q4 FY 2025 missed analyst estimates
Operating loss decreased 48.5% to $6.8 mln in Q4 FY 2025
Outlook
Company did not provide specific guidance for future periods
Result Drivers
DSA REVENUE GROWTH - Driven by increases in biotherapeutic analysis, general toxicology, and surgical services revenue
RMS COST REDUCTION - Reduction in costs related to non-human primates and depreciation improved RMS operating income
LEGAL SETTLEMENT BENEFIT - Legal settlement contributed to decreased operating expenses
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $138.1 mln | $135.61 mln (2 Analysts) |
Q4 EPS | -$0.25 | ||
Q4 Net Income | -$8.60 mln | ||
Q4 Adjusted EBITDA | Miss | $11.8 mln | $12.70 mln (2 Analysts) |
Q4 Operating Income | -$6.80 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Inotiv Inc is $5.00, about 475% above its December 2 closing price of $0.87
Press Release: ID:nGNX8SbVd1
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)